AU2011213703B2 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level - Google Patents

Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level

Info

Publication number
AU2011213703B2
AU2011213703B2 AU2011213703A AU2011213703A AU2011213703B2 AU 2011213703 B2 AU2011213703 B2 AU 2011213703B2 AU 2011213703 A AU2011213703 A AU 2011213703A AU 2011213703 A AU2011213703 A AU 2011213703A AU 2011213703 B2 AU2011213703 B2 AU 2011213703B2
Authority
AU
Australia
Prior art keywords
treatment
conditions
diabetes
increasing
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011213703A
Other versions
AU2011213703A1 (en
Inventor
Hussien A. Al-Shamma
Zhi-Liang Chu
Robert M. Jones
James N. Leonard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Priority to AU2011213703A priority Critical patent/AU2011213703B2/en
Publication of AU2011213703A1 publication Critical patent/AU2011213703A1/en
Application granted granted Critical
Publication of AU2011213703B2 publication Critical patent/AU2011213703B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2011213703A 2005-01-10 2011-08-16 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level Ceased AU2011213703B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011213703A AU2011213703B2 (en) 2005-01-10 2011-08-16 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60/643,086 2005-01-10
US60/683,172 2005-05-19
US60/726,880 2005-10-14
AU2011213703A AU2011213703B2 (en) 2005-01-10 2011-08-16 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2006205164A Division AU2006205164B2 (en) 2005-01-10 2006-01-09 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level

Publications (2)

Publication Number Publication Date
AU2011213703A1 AU2011213703A1 (en) 2011-09-08
AU2011213703B2 true AU2011213703B2 (en) 2013-08-08

Family

ID=

Similar Documents

Publication Publication Date Title
IL184364A0 (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
WO2007124461A3 (en) Glp-1 compounds
ZA200706294B (en) Roflumilast for the treatment of diabetes mellitus
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
IL210856A0 (en) Combination therapy for the treatment of diabetes and related conditions
EP1991218A4 (en) Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives
WO2009020802A3 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
EP1771188A4 (en) Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
HK1087337A1 (en) Use of a hif-alpha stabilizing agent for the preparation of medicament for treatment of diabetes
IL189212A0 (en) Therapeutic agent for diabetes
WO2006053043A3 (en) Methods of treating diabetes mellitus
IL192369A0 (en) Therapeutic agent for diabetes
EP1894588A4 (en) Needle for medical treatment
WO2007080149A8 (en) Treatment of stressed patients
EP1889618A4 (en) Combined drug for treating diabetes
GB0521716D0 (en) Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
EP1750698A4 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
EP1718294A4 (en) Methods for treatment of complications of diabetes
IL189928A0 (en) Thiophene derivatives for the treatment of diabetes
ZA200405342B (en) The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus
ZA200705470B (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
AU2011213703B2 (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
IL191208A (en) Use of fenofibrate or a derivative thereof for the manufacture of a medicament for the treatment of diabetic retinopathy
GB0423173D0 (en) Treatment of diabetes